Header Logo

Connection

Philip Bonomi to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Philip Bonomi has written about Antineoplastic Agents.
Philip Bonomi
Connection Strength
5.162
Antineoplastic Agents
  1. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
    View in: PubMed
    Score: 0.338
  2. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
    View in: PubMed
    Score: 0.327
  3. Epidermal growth factor receptor pathway. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S470-1.
    View in: PubMed
    Score: 0.306
  4. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
    View in: PubMed
    Score: 0.302
  5. Apoptosis. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1061-2.
    View in: PubMed
    Score: 0.284
  6. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1608-13.
    View in: PubMed
    Score: 0.256
  7. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4606-12.
    View in: PubMed
    Score: 0.243
  8. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006 Nov 20; 24(33):5253-8.
    View in: PubMed
    Score: 0.231
  9. Historic evidence and future directions in clinical trial therapy of solid tumors. Oncology (Williston Park). 2006 May; 20(6 Suppl 5):10-8.
    View in: PubMed
    Score: 0.223
  10. Current strategies in the management of lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1667-8.
    View in: PubMed
    Score: 0.215
  11. Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2004 Nov; 6(3):154-61.
    View in: PubMed
    Score: 0.201
  12. Locally advanced NSCLC: current state of the art, treatment and future directions. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S23-30.
    View in: PubMed
    Score: 0.198
  13. Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer. Am J Health Syst Pharm. 2003 Dec 15; 60(24 Suppl 9):S16-21.
    View in: PubMed
    Score: 0.189
  14. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer. 2003 Aug; 41 Suppl 1:S43-8.
    View in: PubMed
    Score: 0.184
  15. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs. 2003 Aug; 12(8):1395-401.
    View in: PubMed
    Score: 0.184
  16. Novel approaches for the treatment of non-small cell lung cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 14):45-9.
    View in: PubMed
    Score: 0.160
  17. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5.
    View in: PubMed
    Score: 0.150
  18. Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer. Chest. 1998 Jan; 113(1 Suppl):13S-16S.
    View in: PubMed
    Score: 0.125
  19. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
    View in: PubMed
    Score: 0.090
  20. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst. 1992 Jul 15; 84(14):1077-84.
    View in: PubMed
    Score: 0.086
  21. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 01; 18(11):3163-9.
    View in: PubMed
    Score: 0.084
  22. Concurrent chemotherapy and thoracic irradiation in non-small cell lung cancer. Hematol Oncol Clin North Am. 1990 Dec; 4(6):1143-58.
    View in: PubMed
    Score: 0.077
  23. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol. 2009 Jun; 32(3):269-73.
    View in: PubMed
    Score: 0.069
  24. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jul; 61(1):82-90.
    View in: PubMed
    Score: 0.063
  25. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4583-8.
    View in: PubMed
    Score: 0.061
  26. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007 Aug 10; 25(23):3448-55.
    View in: PubMed
    Score: 0.060
  27. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer. 2006 May; 7(6):417-9.
    View in: PubMed
    Score: 0.056
  28. Other compounds and targets in non-small cell lung cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 10):S30-6.
    View in: PubMed
    Score: 0.054
  29. Novel treatments in non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):245-67.
    View in: PubMed
    Score: 0.048
  30. Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Cancer Treat Rep. 1983 Feb; 67(2):197-8.
    View in: PubMed
    Score: 0.044
  31. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer. 2002 Dec; 38 Suppl 8:S13-8.
    View in: PubMed
    Score: 0.044
  32. Widespread countervailing genomic responses induced by chemotherapy or radiation as a cause of therapeutic failure. Med Hypotheses. 2000 Jun; 54(6):1000-2.
    View in: PubMed
    Score: 0.037
  33. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206.
    View in: PubMed
    Score: 0.035
  34. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998 Jan 15; 82(2):292-300.
    View in: PubMed
    Score: 0.031
  35. Combined modality treatment for stage III non-small cell lung cancer. Lung Cancer. 1995 Jun; 12 Suppl 2:S41-52.
    View in: PubMed
    Score: 0.026
  36. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). Invest New Drugs. 1995; 13(2):137-41.
    View in: PubMed
    Score: 0.025
  37. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol. 2008 May; 3(5):545-55.
    View in: PubMed
    Score: 0.016
  38. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol. 1986 Dec; 13(4 Suppl 4):9-14.
    View in: PubMed
    Score: 0.014
  39. Megestrol acetate: first-line therapy for advanced breast cancer. Semin Oncol. 1986 Dec; 13(4 Suppl 4):15-9.
    View in: PubMed
    Score: 0.014
  40. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). Cancer Treat Rep. 1982 Jun; 66(6):1417-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.